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Abstract
Due to the increased widespread use of molecular diagnostics, genome sequencing, and microbiome analysis in
microbiology, the field has experienced a massive influx of novel taxa and nomenclature revisions. A subset of
these changes is relevant to the clinical microbiology laboratory, particularly in the context of appropriate
antimicrobial susceptibility testing and epidemiology of emerging infections. However, assimilation of these
changes into daily clinical microbiology laboratory operations can be challenging for a variety of reasons. Recent
taxonomic revisions to Enterobacteriaceae, as well as the genera Borrelia, Mycoplasma, and Mycobacterium, are
reviewed as examples that illustrate discrepancies between resources of revision data, criticisms of potentially
preliminary data, opinions of unnecessary taxonomic revision, and overwhelming data sets for which clinical

relevance is difficult to ascertain. Suggestions for implementation of taxonomic revisions are introduced
(including references to peer-reviewed biennial taxonomy revision compendia), which could be augmented by a
future Clinical and Laboratory Standards Institute guideline.

Introduction
Both bench-level microbiologists and those in supervisory/directorship roles have borne witness to a massive
explosion of microbial nomenclature changes in the past decade. Many of these changes stem from human
microbiome studies, particularly those utilizing genome-sequencing techniques that are becoming increasingly
accessible to the routine clinical microbiology laboratory. It is therefore assumed that discovery of novel taxa
and nomenclature revisions are not likely to cease anytime soon.
Granted, a large proportion of the newly characterized organisms appear to play commensal roles in site-specific
ecology, yet some of these taxa may either be of clinical significance in various patient populations or have their
significance ascertained with future investigations and peer-reviewed studies. Moreover, the increased
utilization of highly accurate identification modalities in the laboratory (e.g., MALDI-TOF [matrix-assisted laser
desorption ionization–time of flight]) may lend additional credence to these potential pathogens. With a focus
on bacterial organisms, this commentary aims to discuss the relevance of microbial taxonomic revision to clinical
microbiology and affiliated disciplines, the means by which taxonomic revisions arise and become publicized,
the conundrums associated with these largely moving targets, and potential future means by which
laboratorians can make these data relevant and useful to their clinical partners.

Taxonomy Changes and Updates—Why Should We Care?
Knowledge of microbial taxonomy updates is essential to the practice of the routine clinical microbiology
laboratory. As one example, laboratories subscribing to the College of American Pathologists accreditation
program have encountered checklist standard MIC.11375 [1], which requires laboratories to assimilate
“taxonomic changes that potentially affect the choice of appropriate antimicrobials to report and/or the
interpretative breakpoints to use.” Reassignment of the former Actinobacillus actinomycetemcomitans to the
genus Haemophilus in the mid-1980s [2] allowed Clinical and Laboratory Standards Institute (CLSI) M100
standard-based antimicrobial susceptibility testing of clinically significant isolates utilizing Haemophilus test
medium in either disk diffusion or broth microdilution format (with the corresponding variable incubation
environments and intervals). The guidelines facilitated the reporting of 9 fluoroquinolone and 15 cephem
susceptibility results, in addition to those derived from trimethoprim/sulfamethoxazole, rifampin, tetracycline,
ampicillin, macrolide, and β-lactam/ β-lactamase inhibitor combination testing.
Subsequent reclassification of the organism into the novel genus Aggregatibacter gen. nov. [3] transitioned CLSI
susceptibility testing guidelines to those specific to HACEK group organisms
(Aggregatibacter spp., Cardiobacterium spp., Eikenella corrodens, and Kingella spp.) and located in the CLSI M45
guideline [4]. As a result, such isolates are assayed only on cation-adjusted Mueller-Hinton broth supplemented
with lysed horse blood while utilizing broth microdilution. Furthermore, the numbers of reportable
fluoroquinolone and cephem agents were reduced to two each. Penicillin and carbapenem susceptibility testing
standards were added to the previously mentioned armamentarium. As with this example, microbiologists
should be vigilant for taxonomic revisions involving organisms that currently fall into generic CLSI classifications,
such as “other non-Enterobacterales” or “Streptococcus viridans group” because amendments to susceptibility
testing and reporting practices may be warranted. The reader is additionally directed to the recent CLSI M100
delineation of methicillin resistance testing standards for coagulase-negative Staphylococcus spp.
The accurate identification and reporting of clinically significant bacteria is also important to the epidemiology of
emerging pathogens. One example of this paradigm resides within the taxon Elizabethkingia anophelis. This

Gram-negative bacillus was first isolated in The Gambia from an Anopheles gambiae midgut [5], and 98.6% and
98.2% 16S rRNA sequence similarity to Elizabethkingia meningoseptica and Elizabethkingia miricola type strains,
respectively, was demonstrated. Initial clinical significance [6] involved a case of neonatal meningitis in Africa,
with preliminary biochemical identification as E. meningoseptica prior to definitive E. anophelis identification via
16S rRNA sequencing of the isolate.
On the basis of geographic location and discovery origin, it was originally hypothesized that mosquito vectors
were central to E. anophelis disease epidemiology. However, Balm et al. [7] chronicled what was thought to be
an E. meningoseptica outbreak in a tertiary Singapore hospital. Follow-up 16S rRNA gene sequencing and wholegenome alignment definitively identified blood and respiratory isolates as E. anophelis [8]. Molecular
epidemiology established relatedness between the clinical isolates and isolates derived from sampling of water
taps/aerators. Additional genetic determinants were consistent with the clinical course (antimicrobial treatment
failure; mortality) in a number of patients. Lau et al. [9] reported three cases of E. anophelis sepsis from Hong
Kong. Neonatal meningitis was additionally diagnosed in two cases, and the third involved maternal
chorioamnionitis. Draft genome sequencing not only confirmed the E. anophelis isolate identity, but also
implicated vertical transmission in two cases.
Lau and colleagues [10] expanded clinical and epidemiologic analysis of Elizabethkingia sp. bacteremia to five
regional Hong Kong hospitals; 81% of Elizabethkingia sp. bacteremic episodes were related to E. anophelis, as
confirmed by 16S rRNA gene sequencing. The mortality rate in these patients was 23.5% (4/17), while no E.
meningoseptica bacteremia cases (n = 3) were fatal. Increased piperacillin and cotrimoxazole resistance was
observed within E. anophelis isolates compared to the limited subset of E. meningoseptica. In summary,
recognition of current bacterial taxonomy can assist in future epidemiologic and prognostic delineations
of Elizabethkingia sp. infections, as well as additional emerging infectious agents.
Finally, reports of novel and revised bacterial taxonomy can potentially be applied to translational research. As
an example, the clinical entity of bacterial vaginosis is a dynamic process of dysbiosis in the female lower genital
tract. Potter et al. [11] recently performed an in silico analysis of 103 Gardnerella sp. genomes as a means of
identifying novel Gardnerella spp. or clarifying existing nomenclature. The authors postulated that a definitive
characterization of vaginal microbiome constituents may identify targets for subsequent investigation of disease
pathogenesis. Combining multiple phylogenetic tools (one of which is described below) with data analysis that
employed conservative adjudication criteria, Potter et al. identified nine Gardnerella genomospecies. In the
process, a recent taxonomic designation of Gardnerella piotii sp. nov. [12] was verified, while those
of Gardnerella leopoldii sp. nov. and Gardnerella swidsinskii sp. nov. were called into question. Knowledge of
intricate bacterial composition could result in future studies that more clearly describe the role that microbes
play in certain disease states compared to endogenous host factors.

Genomics-Based Taxonomy Techniques
Molecular techniques devoted to the genomics-based identification and differentiation of prokaryotes have
improved since the advent of DNA-DNA hybridization. Such modalities have included average amino acid
identity and tetranucleotide frequency analyses (which have now come to serve as initial screening tools), as
well as the discriminatory technique of average nucleotide identity (ANI). Although a 96% ANI cutoff value over
90% coverage of the genome of interest is largely espoused in the realm of prokaryotic taxonomy, even this
technique possesses some limitations. In a study that contributed to the determination of this parameter, Ciufo
et al. [13] identified 335 taxonomic designations for which 10 GenBank (National Center for Biotechnology
Information database) assemblies were available with ANI alignments above 10% coverage. The assemblies were
compared to the submitted type taxon assembly and interpreted as concordant (taxonomic agreement) or
discordant (taxonomic disagreement). The average ANI for concordant comparisons was 97.1%, while the

average for discordant comparisons was 86.3%. However, even at the proposed threshold of 96%, 77
concordant pairs with ANI values falling below that threshold were observed (interpreted as false-negative
matches), while 9 discordant taxon matches with ANI values exceeding that threshold were observed
(interpreted as a failure to confirm the correct species).
Ciufo et al. [13] estimated that two-thirds of genome assemblies residing in GenBank could be confirmed by
using ANI methods compared to a type assembly. An additional limitation of this high-discrimination tool is
revealed by approximately 4% of genome assemblies being misidentified and the remaining 30% being nonevaluable due to a paucity of relevant type strain assemblies. Moreover, an additional moving target involves
variable taxon-specific cutoff values. Clearly defined relationships between members of a genus may result in
high ANI cutoff values, such as those observed for Mycobacterium bovis, Mycobacterium africanum,
and Mycobacterium tuberculosis (approximating 98.8%). ANI cutoffs of 99.99% have been established
for Streptococcus gibsonii, Streptococcus almquistii, and Streptococcus avellaneus. In contrast, less defined intraspecies relationships can result in lower ANI cutoff values (such as 88.50% for Stenotrophomonas
maltophilia and 93.50% for Lactobacillus gasseri) [13].

The Code
Contemporary approaches to the systematic nomenclature of prokaryotes largely had their origin in the plenary
session of the First Congress for Bacteriology, held in 1973. The resulting revision of the International Code of
Nomenclature of Bacteria (the Code) was published in 1975 [14]. Goals of the document included attempts to
simplify the rules of nomenclature (thus encouraging wider use of the Code) and to provide a sound basis for
bacterial systematics. The document was subsequently credited for instituting three major reforms in the field
of prokaryotic taxonomy. First, it resulted in the creation of the Approved Lists of Bacterial Names that took
effect on 1 January 1980. This attempt at standardization established approximately 2,300 valid prokaryotic taxa
and removed thousands of useless names. The lists were subsequently published in the International Journal of
Systematic Bacteriology (known as International Bulletin of Bacteriological Nomenclature and Taxonomy from its
inception in 1951 through 1965 and known as International Journal of Systematic and Evolutionary
Microbiology [IJSEM] since 2000) [15]. Secondly, the Code required that all novel nomenclature be published
in IJSEM. Provisions were additionally established for novel taxa to be published elsewhere and then later
included on IJSEM validation lists. Finally, for valid publication, nomenclatural types were required to be
designated (in part, through the deposit of type strains).
Two major revisions to the Code have ensued, with the most recent edition (now known as The International
Code of Nomenclature of Prokaryotes) published in 2019 [16]. The reader is referred to chapters 1 and 2 of that
resource for an introductory understanding of the general considerations and principles of the Code. Salient
portions of these chapters are summarized here. The first and second general considerations state, “The
progress of bacteriology can be furthered by a precise system of nomenclature accepted by the majority of
bacteriologists of all nations” and “To achieve order in nomenclature, it is essential that scientific names be
regulated by internationally accepted Rules” [16]. An additional consideration describes how the rules of
nomenclature are not designed to determine the relatedness of taxa; they stand, instead, for “assessing the
correctness of the names applied to defined taxa” and for “prescribing the procedures for creating and
proposing new names.”
Nine principles form the basis for the Code. For example, principle 1 [16] outlines essential factors in the
maintenance of nomenclature: (i) stability of names, (ii) avoidance or rejection of names that may cause error or
confusion, (iii) avoidance of useless creation of names, and (iv) the premise that freedom of taxonomic thought
or action is not to be restricted via Code provisions. Principle 4 states that “the primary purpose of giving a name
to a taxon is to supply a means of referring to it rather than to indicate the characters or the history of the

taxon.” Principle 6 declares that the “correct name of a taxon is based upon valid publication, legitimacy and
priority of publication.” Principle 7 adds that “a name of a taxon has no status under the Rules and no claim to
recognition unless it is validly published.” Finally, principle 9 declares that “the name of a taxon should not be
changed without sufficient reason based either on further taxonomic studies or on the necessity of giving up a
nomenclature that is contrary to the Rules of this Code.”

Novel/Revised Taxon Proposal and Publication
As stated above, novel taxa pertinent to prokaryotic species must meet one of two requirements: (i) an original
investigation published in IJSEM or (ii) a study published in an alternative journal with later inclusion on
an IJSEM validation list. As an example, journals that published studies reporting novel Gram-negative taxa in
2018 and 2019 that may be relevant to the practice of clinical microbiology included Journal of Clinical
Microbiology, Antonie Van Leeuwenhoek, Research in Microbiology, Applied and Environmental Microbiology,
Standards in Genomic Sciences, New Microbes and New Infections, and Journal of Microbiology. Six times per
year, IJSEM publishes papers entitled “List of New Names and New Combinations Previously Effectively, but Not
Validly, Published.” To be considered for inclusion on this validation list, authors must submit a copy of the
published manuscript to IJSEM for confirmation that all elements necessary for valid publication have been met.
In addition, type strains are to be deposited into two recognized culture collections in separate nations. Relative
to this provision, journals that published papers regarding revised Gram-negative taxa in 2018 and 2019
include F1000Research, Genes, and Systematic and Applied Microbiology. Finally, IJSEM publishes two papers
per year entitled “Notification of Changes in Taxonomic Opinion Previously Published Outside the IJSEM”. These
findings are simply offered as a service to bacteriology rather than statements of validly published or approved
taxonomy.
Problems may be encountered when attempting to ascertain the relevance of novel or revised taxonomic
designations for clinical microbiology practice. First, the vast majority of novel taxa are derived from
environmental sources. Secondly, when isolates are known to be derived from humans, a number of
publications (particularly those found in IJSEM) simply identify isolates as being derived from a specific specimen
source (including sterile sites) but do not provide contextual clinical data. Therefore, in these scenarios
(including a number of novel taxa derived from blood culture), the clinical significance of the taxa may best be
interpreted as “not established.” Additional studies and published case reports will be necessary to ultimately
determine the clinical significance of several future novel taxa.

Recent Conundrums in the Literature
Additional examples are provided below to illustrate the somewhat confusing nature of bacterial taxonomy
publication/revision, its notification to clinical microbiologists, and its relevance to clinical microbiology practice.
Two major paradigm shifts have occurred within the past 4 years in what was formerly known as the
family Enterobacteriaceae. First, the taxon Enterobacter aerogenes has been revised to Klebsiella aerogenes [17]
as a result of the latter epithet becoming available due to a ruling of illegitimacy for the former Klebsiella
mobilis. Clinical microbiologists have expressed reservations that this taxonomic revision may influence
suboptimal antimicrobial therapy of infections caused by the former Enterobacter aerogenes, particularly when
considering predicted antimicrobial susceptibility profiles of the
genera Klebsiella and Enterobacter (cephamycin, first-generation cephem, and b-lactam/b-lactamase inhibitor
combination agents) and the potential induction of AmpC chromosomal beta-lactamases associated
with Enterobacter spp. [18]. A second paradigm shift involves reclassification of
(former) Enterobacteriaceae genera, with the creation of six novel genera within the new
order Enterobacterales ord. nov. Adeolu et al. [19] proposed these changes on the basis of genomic similarity
and phylogenetic reconstructions of 1,548 core proteins, 53 ribosomal proteins, and four multilocus sequence

analysis proteins. The current taxonomic status of the order Enterobacterales, according to updates by the online service List of Prokaryotic Names with Standing in Nomenclature (LPSN), is provided in Table 1. Noteworthy
within the table are one family (Thorselliaceae) and eight genus
(including Calymmatobacterium and Plesiomonas) designations that were not investigated by Adeolu et al. On
the other hand, these researchers
included Kosakonia spp., Lelliottia spp., Pluralibacter spp., Pseudocitrobacter spp., Rosenbergiella spp.,
and Siccibacter spp. in their investigation, though these genera are not included in the real-time LPSN database.
Such discrepancies may provide an additional moving target for the clinical microbiologist in the attempt to
ascertain clinically relevant shifts in prokaryotic taxonomy.
Table 1. Subdivisions of the order Enterobacterales according to the List of Prokaryotic Names with Standing in
Nomenclature (http://www.bacterio.net/-classifphyla.html; accessed 20 December 2019)
Family

Genus

Budviciaceae

Budvicia (type genus)
Leminorella
Pragia

Enterobacteriaceae Biostraticola
Buttiauxella
Calymmatobacteriuma
Cedecea
Citrobacter
Cronobacter
Enterobacillus
Enterobacter
Escherichia (type genus)
Franconibacter
Gibbsiella
Izhakiella
Klebsiella
Kluyvera
Kosakoniab
Leclercia
Lelliottiab
Levineaa
Mangrovibacter
Metakosakoniaa
Plesiomonasa
Pluralibacterb
Pseudescherichiaa
Pseudocitrobacterb
Raoultella
Rosenbergiellab
Saccharobacter
Salmonella
Shigella
Shimwellia
Siccibacterb
Trabulsiella

Family

Genus
Yokenella

Erwiniaceae

Buchnera
Erwinia (type genus)
Mixtac
Pantoea
Phaseolibacter
Tatumella
Wigglesworthia

Hafniaceae

Edwardsiella
Hafnia (type genus)
Obesumbacterium

Morganellaceae

Arsenophonus
Cosenzaea
Moellerella
Morganella (type genus)
Photorhabdus
Proteus
Providencia
Xenorhabdus

Pectobacteriaceae

Brenneria
Dickeya
Lonsdalea
Pectobacterium (type genus)
Sodalis

Thorselliaceaed

Coetzeeaa
Thorsellia (type genus)a

Yersiniaceae

Chania
Ewingella
Rahnella
Rouxiella
Samsonia
Serratia
Yersinia (type genus)

Unassigned

Phytobactera

Genus not discussed in 2016 reclassification proposal of Adeolu et al. [19].
Genus discussed in 2016 proposal of Adeolu et al. but not characterized as Enterobacterales in the List of
Prokaryotic Names with Standing in Nomenclature.
c
Novel taxonomic designation published by IJSEM following the 2016 proposal of Adeolu et al.
d
Family not discussed in 2016 proposal of Adeolu et al.
a

b

In 2014, Adeolu and Gupta [20] proposed the delineation of 14 Borrelia spp. into the novel genus Borreliella gen.
nov. (Table 2). Eleven of these novel taxa have been validated by IJSEM [21, 22]. The original basis for this
delineation was the demonstration of characteristic profiles of conserved molecular signature inserts/deletions

(CSI) and conserved signature proteins (CSP) among Borrelia spp. that cause Lyme borreliosis and those that
cause relapsing fever. These findings, when combined with ANI data, pathogenicity profiles, and arthropod
vectors, resulted in the assignment of Lyme borreliosis spirochetes to the novel genus Borreliella, with retention
of the genus Borrelia largely for relapsing fever spirochetes. Five novel Borrelia sp. taxa (Table 2), either derived
from clinically ill patients or isolated from Ixodes sp. vectors, published in IJSEM following the report of Adeolu
and Gupta [20] were not subject to reclassification. Controversy over the Borrelia sp./Borreliella sp. delineation
has ensued in several rebuttals [23, 24, 25, 26, 27]. In one publication [23], a consortium of 27 scientists
contended that CSI and CSP data were too preliminary in nature to support the reclassification. Furthermore,
case reports describing overlapping clinical and epidemiologic data did not favor a strong delineation between
the genera. In a second rebuttal [27], Margos et al. criticized the number of species (11 of 29 named and
proposed species relative to relapsing fever; 11 of 22 Lyme borreliosis species) investigated in the original
report, as well as the omission of other Borrelia spp. that may signify additional diversity within the
genus Borrelia.
Table 2. Proposal for division of genus Borrelia, with establishment of Borreliella gen. nov. (based on 2014
publication of Adeolu and Gupta [20])
Maintain Borrelia genus designation Transfer to genus Borreliella gen. nov.
Borrelia anserina (type species)
Borrelia baltazardii
Borrelia bissettiaea
Borrelia brasiliensis
Borrelia californiensisa
Borrelia caucasica
Borrelia coriaceae
Borrelia crocidurae
Borrelia dugesii
Borrelia duttonii
Borrelia graingeri
Borrelia harveyi
Borrelia hermsii
Borrelia hispanica
Borrelia laneia
Borrelia latyschewii
Borrelia mayoniia
Borrelia mazzottii
Borrelia miyamotoi
Borrelia parkeri
Borrelia persica
Borrelia recurrentis
Borrelia theileri
Borrelia tillae
Borrelia turcica
Borrelia turicatae
Borrelia venezuelensis
Borrelia yangtzensisa

Borreliella afzelii comb. nov.b
Borreliella americana comb. nov.b
Borreliella bavariensis comb. nov.c
Borreliella burgdorferi comb. nov. (type species)c
Borreliella carolinensis comb. nov.c
Borreliella garinii comb. nov.c
Borreliella japonica comb. nov.c
Borreliella kurtenbachii comb. nov.c
Borreliella lusitaniae comb. nov.
Borreliella sinica comb. nov.c
Borreliella spielmanii comb. nov.c
Borreliella tanukii comb. nov.
Borreliella turdi comb. nov.
Borreliella valaisiana comb. nov.b

Novel taxonomic designation published in IJSEM following the 2014 reclassification proposal of Adeolu and
Gupta [20].
b
Added per IJSEM validation list 182 in 2018 [21].
a

c

Added per IJSEM validation list 163 in 2015 [22].

In a comprehensive report published in 2018, Gupta et al. [28] proposed the removal of several former members
of the genus Mycoplasma and placement into the novel genera Malacoplasma gen. nov., Mesomycoplasma gen.
nov., Metamycoplasma gen. nov., Mycoplasmoides gen. nov., and Mycoplasmopsis gen. nov. (Table 3). The basis
for the delineation of the five novel genera ranged from four to seven characteristic CSI; 75% of the 105
reassigned species have been validated by IJSEM [29, 30]. Type species within these genera
include Malacoplasma iowae comb. nov., Mesomycoplasma hyopneumoniae comb. nov., Metamycoplasma
hominis comb. nov., Mycoplasmoides pneumoniae comb. nov., and Mycoplasmopsis agalactiae comb. nov. The
emerging sexually transmitted infection agent Mycoplasma genitalium has been reclassified as Mycoplasmoides
genitalium comb. nov. The new genera are encompassed by the families Metamycoplasmataceae fam. nov.
and Mycoplasmoidaceae fam. nov.
Table 3. Proposal for reclassification of selected members of the genus Mycoplasma, with establishment of the
novel genera Malacoplasma gen. nov., Mesomycoplasma gen. nov., Metamycoplasma gen.
nov., Mycoplasmoides gen. nov., and Mycoplasmopsis gen. nov. (based on 2018 publication of Gupta et al. [28])
Novel genus designation

Included genus/species designations

Malacoplasma gen. nov.

Malacoplasma iowae comb. nov. (type species)a
Malacoplasma microti comb. nov.a
Malacoplasma muris comb. nov.a
Malacoplasma penetrans comb. nov.a,b

Mesomycoplasma gen. nov. Mesomycoplasma bovoculi comb. nov.
Mesomycoplasma collis comb. nov.
Mesomycoplasma conjunctivae comb. nov.a
Mesomycoplasma dispar comb. nov.
Mesomycoplasma flocculare comb. nov.a
Mesomycoplasma hyopneumoniae comb. nov. (type species)a
Mesomycoplasma hyorhinis comb. nov.a
Mesomycoplasma lagogenitalium comb. nov.a
Mesomycoplasma moatsii comb. nov.a
Mesomycoplasma mobile comb. nov.
Mesomycoplasma molare comb. nov.a,c
Mesomycoplasma neurolyticum comb. nov.a
Mesomycoplasma ovipneumoniae comb. nov.a
Metamycoplasma gen. nov. Metamycoplasma alkalescens comb. nov.a
Metamycoplasma anseris comb. nov.
Metamycoplasma arthritidis comb. nov.a,b
Metamycoplasma auris comb. nov.a
Metamycoplasma buccale comb. nov.a,b
Metamycoplasma canadense comb. nov.a
Metamycoplasma cloacale comb. nov.a
Metamycoplasma equirhinis comb. nov.a
Metamycoplasma falconis comb. nov.
Metamycoplasma faucium comb. nov.a,b
Metamycoplasma gateae comb. nov.a
Metamycoplasma gypis comb. nov.
Metamycoplasma hominis comb. nov. (type species)a,b

Novel genus designation

Included genus/species designations
Metamycoplasma hyosynoviae comb. nov.a
Metamycoplasma indiense comb. nov.
Metamycoplasma neophronis comb. nov.a
Metamycoplasma orale comb. nov.a,b
Metamycoplasma phocae comb. nov.
Metamycoplasma phocicerebrale comb. nov.a
Metamycoplasma salivarium comb. nov.a,b
Metamycoplasma spumans comb. nov.a
Metamycoplasma sualvi comb. nov.a
Metamycoplasma subdolum comb. nov.

Mycoplasmoides gen. nov.

Mycoplasmoides alvi comb. nov.a
Mycoplasmoides amphoriforme comb. nov.b
Mycoplasmoides cavipharyngis comb. nov.
Mycoplasmoides fastidiosum comb. nov.a
Mycoplasmoides gallisepticum comb. nov.a
Mycoplasmoides genitalium comb. nov.a,b
Mycoplasmoides imitans comb. nov.
Mycoplasmoides pirum comb. nov.a,b
Mycoplasmoides pneumoniae comb. nov. (type species)a,b
Mycoplasmoides testudinis comb. nov.

Mycoplasmopsis gen. nov.

Mycoplasmopsis adleri comb. nov.a
Mycoplasmopsis agalactiae comb. nov. (type species)a
Mycoplasmopsis agassizii comb. nov.a
Mycoplasmopsis alligatoris comb. nov.a
Mycoplasmopsis anatis comb. nov.a
Mycoplasmopsis arginini comb. nov.a,b
Mycoplasmopsis bovigenitalium comb. nov.a
Mycoplasmopsis bovirhinis comb. nov.a
Mycoplasmopsis bovis comb. nov.a
Mycoplasmopsis buteonis comb. nov.
Mycoplasmopsis californica comb. nov.a
Mycoplasmopsis canis comb. nov.a,b
Mycoplasmopsis caviae comb. nov.a,b
Mycoplasmopsis ciconiae comb. nov.a
Mycoplasmopsis citelli comb. nov.a
Mycoplasmopsis columbinasalis comb. nov.a
Mycoplasmopsis columbina comb. nov.
Mycoplasmopsis columboralis comb. nov.a
Mycoplasmopsis corogypsi comb. nov.
Mycoplasmopsis cricetuli comb. nov.a
Mycoplasmopsis crocodyli comb. nov.
Mycoplasmopsis cynos comb. nov.a
Mycoplasmopsis edwardii comb. nov.a,b
Mycoplasmopsis elephantis comb. nov.
Mycoplasmopsis equigenitalium comb. nov.a
Mycoplasmopsis felifaucium comb. nov.a
Mycoplasmopsis felis comb. nov.b,d

Novel genus designation

Included genus/species designations
Mycoplasmopsis fermentans comb. nov.a,b
Mycoplasmopsis gallinacea comb. nov.a
Mycoplasmopsis gallinarum comb. nov.a
Mycoplasmopsis gallopavonis comb. nov.a
Mycoplasmopsis glycophila comb. nov.a
Mycoplasmopsis hyopharyngis comb. nov.a
Mycoplasmopsis iguanae comb. nov.
Mycoplasmopsis iners comb. nov.a
Mycoplasmopsis leonicaptivi comb. nov.
Mycoplasmopsis leopharyngis comb. nov.
Mycoplasmopsis lipofaciens comb. nov.a
Mycoplasmopsis lipophila comb. nov.a,b
Mycoplasmopsis maculosa comb. nov.a,b
Mycoplasmopsis meleagridis comb. nov.a
Mycoplasmopsis mucosicanis comb. nov.a
Mycoplasmopsis mustelae comb. nov.a
Mycoplasmopsis opalescens comb. nov.a
Mycoplasmopsis oxoniensis comb. nov.
Mycoplasmopsis phocirhinis comb. nov.a
Mycoplasmopsis primatum comb. nov.a,b
Mycoplasmopsis pullorum comb. nov.a
Mycoplasmopsis pulmonis comb. nov.a,b
Mycoplasmopsis simbae comb. nov. Mycoplasmopsis synoviae comb. nov.a
Mycoplasmopsis testudinea comb. nov.
Mycoplasmopsis verecunda comb. nov.a

Added per IJSEM validation list 184 in 2018 [29].
Species detected from human clinical specimen.
c
Originally published as Metamycoplasma molaris [28] but corrected by IJSEM [29].
d
Added per IJSEM validation list 184 in 2018 [30].
a

b

A group of 20 researchers, writing as members of the International Committee on Systematics of Prokaryotes'
subcommittee on the taxonomy of Mollicutes, formally recommended rejection of these findings [31]. While this
group actually viewed the core genome sequence investigations in a favorable light, and even as vindication of
efforts in the field of mycoplasmatology, the researchers collectively characterized the nomenclature changes as
an “unnecessary over-reach verging on taxonomic vandalism.” The denunciation continued by citing several
elements of the Code. Three tenets of principle 1 were invoked, namely, (i) aim for stability of names, (ii) avoid
or reject the use of names that may cause error or confusion, and (iii) avoid the useless creation of names. Balish
et al. [31] explained that the renaming of approximately 40 extant species (with the original nomenclature
[basonyms] retaining standing in the nomenclature) would destabilize the nomenclature for microbiologists and
regulatory agencies who use these names for applied and clinical purposes. Beyond the avoidance of names that
may cause error or confusion, Balish et al. cited a chapter 3 rule that states, “A name may be placed on [the list
of rejected names (nomina rejicienda)] for various reasons, including…a perilous name, i.e., a name whose
application is likely to lead to accidents endangering health or life or both or of serious economic
consequences.” Referred taxa in this example include both human (M. genitalium, M. pneumoniae, and M.
hominis) and veterinary (M. agalactiae, M. bovis, and M. hyopneumoniae) pathogens, some of which are agents

reportable to selected world and U.S. health agencies, which may have downstream treatment, import/export,
and quarantine consequences.
Balish et al. [31] also suggested that numerous “comb. nov.” designations were created by Gupta et al. [28] for
the purpose of signifying a presumed history of taxon descent from a common ancestor (contravention of
principle 4); numerous “comb. nov.” designations did not possess sufficient justification for existence (a
rationale that would have outweighed concerns regarding medical and agricultural utility; contravention of
principle 9); numerous “comb. nov.” designations were derived from analyses that would encounter difficulty
with respect to future independent experimental replication (Code rule 28b); and, numerous “comb. nov.”
designations were based on selected diagnostic characters of the genomes that were used to alter current
taxonomic restrictions (Code rule 37b). Moreover, Balish et al. even contended that at least two of the
associated novel taxonomic designations contradict recommendation 6 of chapter 3, which states, “Avoid names
of epithets that are very long or difficult to pronounce.”
While revisions to the formerly constituted genera Borrelia and Mycoplasma have been challenged for largely
scientific and practical reasons, respectively, the recent and perhaps overwhelming revision of the
genus Mycobacterium proposed by Gupta et al. [32] may present additional problems for the clinical
microbiologist. While mycobacteria of greater clinical significance, such as Mycobacterium tuberculosis (and its
subspecies), Mycobacterium bovis (and its subspecies), Mycobacterium leprae, Mycobacterium kansasii,
Mycobacterium avium (and its subspecies), Mycobacterium genavense, and Mycobacterium scrofulaceum, were
not subject to this revision, 114 Mycobacterium spp. were reassigned to the novel genera Mycolicibacter gen.
nov., Mycolicibacillus gen. nov., Mycobacteroides gen. nov., and Mycolicibacterium gen. nov (Table 4). 97% of
these novel taxonomic designations have been validated by IJSEM [33]. Both the genera Mycobacteroides (type
species Mycobacteroides abscessus comb. nov.) and Mycolicibacterium (type species Mycolicibacterium
fortuitum comb. nov.) are comprised of rapidly growing mycobacteria. Gupta et al. [32] further noted that the
two genera can be differentiated by 3-day arylsulfatase and nitrate reductase testing results (both positive
for Mycolicibacterium spp.). The genera Mycolicibacter and Mycolicibacillus are comprised of organisms that
require more than 7 days for growth; differentiating morphologic and biochemical traits were not provided. The
major issue presented to the clinical microbiologist with respect to this genus reclassification is related largely to
clinical relevance. Many of the species are saprophytic and are considered non-pathogenic to humans. Case
reports regarding organism isolation (or nucleic acid detection) can be found in the medical literature for several
of the species; however, in many of these scenarios, true clinical significance is difficult to establish. This calls
into the question the necessity of laborious and persistent laboratory vigilance to recognize and assimilate such
taxonomic revisions.
Table 4. Proposal for reclassification of selected members of genus Mycobacterium, with establishment of the
novel genera Mycolicibacter gen. nov., Mycolicibacillus gen. nov., Mycobacteroides gen. nov.,
and Mycolibacterium gen. nov. (based on 2018 publication of Gupta [32])
Novel genus designation

Included genus/species designations

Mycolicibacter gen. nov.

Mycolicibacter algericus comb. nov.a
Mycolicibacter arupensis comb. nov.a,b
Mycolicibacter engbaekii comb. nov.a
Mycolicibacter heraklionensis comb. nov.a,b
Mycolicibacter hiberniae comb. nov.a,b
Mycolicibacter icosiumassiliensis sp. nov.c
Mycolicibacter kumamotonensis comb. nov.a,b
Mycolicibacter longobardus comb. nov.a,b
Mycolicibacter minnesotensis comb. nov.a

Novel genus designation

Included genus/species designations
Mycolicibacter nonchromogenicus comb. nov.a,b
Mycolicibacter paraterrae comb. nov.a,b
Mycolicibacter senuensis comb. nov.a
Mycolicibacter sinensis sp. nov.c
Mycolicibacter terrae comb. nov. (type species)a,b
Mycolicibacter virginiensis comb. nov.b

Mycolicibacillus gen. nov.

Mycolicibacillus koreensis comb. nov.a,b
Mycolicibacillus parakoreensis comb. nov.a,b
Mycolicibacillus trivialis comb. nov. (type species)a,b

Mycobacteroides gen. nov.

Mycobacteroides abscessus comb. nov. (type species)a,b
Mycobacteroides abscessus subsp. abscessus comb. nov.a,b
Mycobacteroides abscessus subsp. bolletii comb. nov.a,b
Mycobacteroides abscessus subsp. massiliense comb. nov.a,b
Mycobacteroides chelonae comb. nov.a,b
Mycobacteroides franklinii comb. nov.a,b
Mycobacteroides immunogenum comb. nov.a,b
Mycobacteroides salmoniphilum comb. nov.a
Mycobacteroides saopaulense comb. nov.a,b

Mycolicibacterium gen. nov. Mycolicibacterium agri comb. nov.a
Mycolicibacterium aichiense comb. nov.a
Mycolicibacterium alvei comb. nov.a,b
Mycolicibacterium anyangense comb. nov.a
Mycolicibacterium arabiense comb. nov.a
Mycolicibacterium arcueilense comb. nov.a
Mycolicibacterium aromaticivorans comb. nov.a
Mycolicibacterium aubagnense comb. nov.a,b
Mycolicibacterium aurum comb. nov..a,b
Mycolicibacterium austroafricanum comb. nov..a,b
Mycolicibacterium bacteremicum comb. nov..a,b
Mycolicibacterium boenickei comb. nov..a,b
Mycolicibacterium brisbanense comb. nov..a,b
Mycolicibacterium brumae comb. nov..a,b
Mycolicibacterium canariasense comb. nov..a,b
Mycolicibacterium celeriflavum comb. nov..a,b
Mycolicibacterium chitae comb. nov.a
Mycolicibacterium chlorophenolicum comb. nov..a,b
Mycolicibacterium chubuense comb. nov.a
Mycolicibacterium conceptionense comb. nov..a,b
Mycolicibacterium confluentis comb. nov..a,b
Mycolicibacterium cosmeticum comb. nov..a,b
Mycolicibacterium crocinum comb. nov.a
Mycolicibacterium diernhoferi comb. nov.a
Mycolicibacterium doricum comb. nov..a,b
Mycolicibacterium duvalii comb. nov..a,b
Mycolicibacterium elephantis comb. nov..a,b
Mycolicibacterium fallax comb. nov.a

Novel genus designation

Included genus/species designations
Mycolicibacterium farcinogenes comb. nov..a,b
Mycolicibacterium flavescens comb. nov..a,b
Mycolicibacterium fluoranthenivorans comb. nov..a,b

Mycolicibacterium gen. nov. Mycolicibacterium fortuitum comb. nov. (type species).a,b
Mycolicibacterium fortuitum subsp. acetamidolyticum comb. nov..a,b
Mycolicibacterium fortuitum subsp. fortuitum comb. nov..a,b
Mycolicibacterium frederiksbergense comb. nov..a,b
Mycolicibacterium gadium comb. nov..a,b
Mycolicibacterium gilvum comb. nov.a
Mycolicibacterium goodii comb. nov.b
Mycolicibacterium hassiacum comb. nov..a,b
Mycolicibacterium helvum comb. nov.a
Mycolicibacterium hippocampi comb. nov.a
Mycolicibacterium hodleri comb. nov..a,b
Mycolicibacterium holsaticum comb. nov..a,b
Mycolicibacterium houstonense comb. nov..a,b
Mycolicibacterium insubricum comb. nov..a,b
Mycolicibacterium iranicum comb. nov..a,b
Mycolicibacterium komossense comb. nov.a
Mycolicibacterium litorale comb. nov..a,b
Mycolicibacterium llatzerense comb. nov..a,b
Mycolicibacterium lutetiense comb. nov.a
Mycolicibacterium madagascariense comb. nov..a,b
Mycolicibacterium mageritense comb. nov..a,b
Mycolicibacterium malmesburyense comb. nov.a
Mycolicibacterium monacense comb. nov..a,b
Mycolicibacterium montmartrense comb. nov.
Mycolicibacterium moriokaense comb. nov..a,b
Mycolicibacterium mucogenicum comb. nov..a,b
Mycolicibacterium murale comb. nov.a
Mycolicibacterium neoaurum comb. nov..a,b
Mycolicibacterium neworleansense comb. nov..a,b
Mycolicibacterium novocastrense comb. nov..a,b
Mycolicibacterium obuense comb. nov.a
Mycolicibacterium oryzae comb. nov.a
Mycolicibacterium pallens comb. nov.a
Mycolicibacterium parafortuitum comb. nov..a,b
Mycolicibacterium peregrinum comb. nov..a,b
Mycolicibacterium phlei comb. nov..a,b
Mycolicibacterium phocaicum comb. nov..a,b
Mycolicibacterium porcinum comb. nov..a,b
Mycolicibacterium poriferae comb. nov..a,b
Mycolicibacterium psychrotolerans comb. nov.a
Mycolicibacterium pulveris comb. nov..a,b
Mycolicibacterium pyrenivorans comb. nov.a
Mycolicibacterium rhodesiae comb. nov..a,b
Mycolicibacterium rufum comb. nov.a
Mycolicibacterium rutilum comb. nov.a

Novel genus designation

Included genus/species designations
Mycolicibacterium sarraceniae comb. nov.a
Mycolicibacterium sediminis comb. nov.a
Mycolicibacterium senegalense comb. nov..a,b
Mycolicibacterium septicum comb. nov..a,b
Mycolicibacterium setense comb. nov..a,b
Mycolicibacterium smegmatis comb. nov..a,b
Mycolicibacterium sphagni comb. nov.a
Mycolicibacterium thermoresistibile comb. nov..a,b
Mycolicibacterium tokaiense comb. nov..a,b
Mycolicibacterium tusciae comb. nov..a,b
Mycolicibacterium vaccae comb. nov..a,b
Mycolicibacterium vanbaalenii comb. nov.a
Mycolicibacterium wolinskyi comb. nov..a,b

Added per IJSEM validation list 181 in 2018 [33].
Species detected from human clinical specimen.
c
Proposed new species of Mycolicibacter; designation not validated by IJSEM.
a

b

What Should We Do Now?

One of the major challenges for the clinical microbiologist in managing novel and changing prokaryotic
taxonomy is simply becoming cognizant of the information. As mentioned above, publication of novel and
revised taxa may occur through multiple outlets encompassing the fields of bacteriology, phylogenomics, and
clinical microbiology. However, the reference standard for official recognition of bacterial taxa is IJSEM, through
either original publication or inclusion on a validation list. The clinical microbiologist is encouraged to peruse this
journal on a regular basis to ascertain taxonomic novelties that could affect daily practice. Recognizing potential
time constraints of the laboratory director, supervisor, or bench technologist (particularly in light of the fact that
the majority of bacterial taxonomy publications do not possess clinical relevance), at least two journals have
committed to providing biennial compilations of microbial taxonomy revisions.
Diagnostic Microbiology and Infectious Diseases has published taxonomic updates on proposed classification
and nomenclature changes for bacteria of medical importance since 2015 [34]. Journal of Clinical
Microbiology has published microbial taxonomy updates in the fields of bacteriology [18], mycology, virology,
parasitology, and mycobacteriology since 2017 [35]. Approaches to this task have slightly diverged in recent
years. The latest Diagnostic Microbiology and Infectious Diseases report by Janda [34] restricts inclusion to novel
taxa characterized by at least five strains (or taxa with substantial clinical correlation) and to taxonomic revisions
having major clinical significance. Entries are sampled from a variety of journals with bacteriology and taxonomy
focus, and not all the data are validated by IJSEM. Similarly, the Journal of Clinical Microbiology bacteriology
compendia are based on isolates derived from human sources; however, these summaries are designed to cast a
broader net with the thought that future case reports can validate the clinical significance of the taxa. In fact,
clinical significance was later elucidated for Klebsiella michiganensis [36], a novel taxon that was listed in an
initial Journal of Clinical Microbiology taxonomic summary. The majority of Journal of Clinical
Microbiology entries are originally published in or subsequently validated by IJSEM.
In terms of laboratory adoption of taxonomic changes, Janda [37] outlined a multi-faceted approach, with focus
on taxa characterized by several clinical isolates (optimally from sterile sources) or by strong clinical correlation.
Beyond consistent peer-reviewed literature searches or reliance on biennial updates, it was recommended that
laboratory adoption of novel taxa (particularly from non-IJSEM journals) not take place within the first year

following publication (to allow ultimate validation by IJSEM). Taxonomic revisions can sometimes involve less
stringency and may be adopted in a more timely fashion. A 1- to 2-year period in which the former genus
designation is parenthetically incorporated into laboratory reports [Klebsiella (Enterobacter) aerogenes, as an
example] has further been recommended prior to using the official taxonomic status.

Summary
A past publication [38] loosely compared the moving target of bacterial taxonomy to cautionary tales of the
folklore genre. Our clinical partners encounter vast amounts of informatics and data on a daily basis. The means
by which we microbiologists communicate these data (in clinically relevant fashion) may tremendously impact
the care and even safety of our patients. Beyond this, the fields of therapeutics, diagnostics, pathogenesis, and
epidemiology may also be influenced by nomenclature changes. In an effort to assist clinical and veterinary
microbiology laboratories in managing and implementing taxonomic revisions in relevant fashion, CLSI has
approved and appointed a document development committee charged with preparing a “Guideline for
Implementation of Taxonomy Nomenclature Changes.” This subcommittee is not designed to usurp the role of a
taxonomist, but instead has the overarching goal of providing guidelines for the adoption and use of clinically
relevant taxonomic changes. The document will be revised every 2 years, incorporating new scientific
publications and feedback from users through the CLSI process; the document is anticipated to be published in
2022.
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